Literature DB >> 31310316

A Cohort Analysis of Clinical and Ultrasound Variables Predicting Cancer Risk in 20,001 Consecutive Thyroid Nodules.

Trevor E Angell1, Rie Maurer2, Zhihong Wang1,3, Matthew I Kim1, Caroline A Alexander1, Justine A Barletta4, Carol B Benson5, Edmund S Cibas4, Nancy L Cho6, Gerard M Doherty6, Peter M Doubilet5, Mary C Frates5, Atul A Gawande6, Jeff F Krane4, Ellen Marqusee1, Francis D Moore6, Matthew A Nehs6, P Reed Larsen1, Erik K Alexander1.   

Abstract

CONTEXT: Assessing thyroid nodules for malignancy is complex. The impact of patient and nodule factors on cancer evaluation is uncertain.
OBJECTIVES: To determine precise estimates of cancer risk associated with clinical and sonographic variables obtained during thyroid nodule assessment.
DESIGN: Analysis of consecutive adult patients evaluated with ultrasound-guided fine-needle aspiration for a thyroid nodule ≥1 cm between 1995 and 2017. Demographics, nodule sonographic appearance, and pathologic findings were collected. MAIN OUTCOME MEASURES: Estimated risk for thyroid nodule malignancy for patient and sonographic variables using mixed-effect logistic regression.
RESULTS: In 9967 patients [84% women, median age 53 years (range 18 to 95)], thyroid cancer was confirmed in 1974 of 20,001 thyroid nodules (9.9%). Significant ORs for malignancy were demonstrated for patient age <52 years [OR: 1.82, 95% CI (1.63 to 2.05), P < 0.0001], male sex [OR: 1.68 (1.45 to 1.93), P < 0.0001], nodule size [OR: 1.30 (1.14 to 1.49) for 20 to 19 mm, OR: 1.59 (1.34 to 1.88) for 30 to 39 mm, and OR: 1.71 (1.43 to 2.04) for ≥40 mm compared with 10 to 19 mm, P < 0.0001 for all], cystic content [OR: 0.43 (0.37 to 0.50) for 25% to 75% cystic and OR: 0.21 (0.15 to 0.28) for >75% compared with predominantly solid, P < 0.0001 for both], and the presence of additional nodules ≥1 cm [OR: 0.69 (0.60 to 0.79) for two nodules, OR: 0.41 (0.34 to 0.49) for three nodules, and OR: 0.19 (0.16 to 0.22) for greater than or equal to four nodules compared with one nodule, P < 0.0001 for all]. A free online calculator was constructed to provide malignancy-risk estimates based on these variables.
CONCLUSIONS: Patient and nodule characteristics enable more precise thyroid nodule risk assessment. These variables are obtained during routine initial thyroid nodule evaluation and provide new insights into individualized thyroid nodule care.
Copyright © 2019 Endocrine Society.

Entities:  

Mesh:

Year:  2019        PMID: 31310316     DOI: 10.1210/jc.2019-00664

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  SuperSonic shear imaging for the differentiation between benign and malignant thyroid nodules: a meta-analysis.

Authors:  Y Chen; B Dong; Z Jiang; Q Cai; L Huang; H Huang
Journal:  J Endocrinol Invest       Date:  2022-03-01       Impact factor: 4.256

2.  Relationship between TSHR, BRAF and PIK3CA gene copy number variations and thyroid nodules.

Authors:  Xiaoli Shi; Mengying Qu; Xing Jin; Lixiang Liu; Fangang Meng; Hongmei Shen
Journal:  Endocrine       Date:  2021-01-11       Impact factor: 3.633

3.  [Detection rate of thyroid nodules in routine health check-up and its influencing factors: a 10-year survey of 309 576 cases].

Authors:  Xiaoying Lai; Ping Ouyang; Hong Zhu; Shengli An; Lijuan Xia; Yiting Yao; Han Zhang; Zhi Li; Kan Deng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-02-29

4.  The gray zone of thyroid nodules: Using a nomogram to provide malignancy risk assessment and guide patient management.

Authors:  Elham Yousefi; Gloria H Sura; Jonathan Somma
Journal:  Cancer Med       Date:  2021-03-24       Impact factor: 4.452

5.  Point of Care Measurement of Body Mass Index and Thyroid Nodule Malignancy Risk Assessment.

Authors:  Sara Ahmadi; Theodora Pappa; Alex S Kang; Alexandra K Coleman; Iñigo Landa; Ellen Marqusee; Matthew Kim; Trevor E Angell; Erik K Alexander
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-11       Impact factor: 5.555

6.  Clinical experience following implementation of routine SPECT-CT imaging following 131-iodine administration for thyroid cancer.

Authors:  Sara Ahmadi; Alexandra Coleman; Nathalie Silva de Morais; Iñigo Landa; Theodora Pappa; Alex Kang; Matthew I Kim; Ellen Marqusee; Erik K Alexander
Journal:  Endocr Connect       Date:  2022-05-25       Impact factor: 3.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.